Biocon Gains FDA Approval for Yesintek Ustekinumab Prefilled Autoinjector in U.S. Market

Biocon's FDA approval of Yesintek® (ustekinumab-kfce) in a single-dose prefilled autoinjector format signals a maturing phase in biosimilar device strategy, one where combination product pathways are becoming as consequential as the biological comparability exercise itself. For QA directors and regulatory affairs leads managing biosimilar portfolios, the approval underscores how device-drug combination submissions are reshaping the competitive landscape in the U.S. biosimilar market.

Yesintek, a biosimilar referencing Stelara® (ustekinumab), had previously entered the U.S. market in vial format. The autoinjector approval extends the product's delivery options, a step that requires demonstrating human factors validation, container closure integrity, and device-constituent compatibility under 21 CFR Part 4 combination product regulations, requirements that sit alongside the core biologics license application data package.

The prefilled autoinjector format has become a recurring feature in late-stage biosimilar development, particularly for subcutaneous biologics where patient handling and dose accuracy carry regulatory weight. For plant heads overseeing fill-finish and device assembly operations, this approval reflects the operational complexity of qualifying a new primary container system post-licensure, a process that typically involves comparability protocols, updated process validation, and potential labeling supplements under ICH Q10 lifecycle management principles.

Biocon's biosimilar unit, developed in partnership with Viatris, has built a U.S. regulatory track record across multiple molecules. The Yesintek autoinjector approval adds a device dimension to that record, relevant to any manufacturer evaluating whether to pursue combination product designation early in development or defer to a post-approval supplement strategy.

For regulatory affairs teams, the approval also reinforces FDA's continued willingness to process device format extensions for approved biosimilars within existing BLA frameworks, provided human factors and device constituent data meet agency expectations, a pathway that carries its own inspection and documentation burden distinct from the original biologics review.

The Yesintek autoinjector approval will be measured, in part, by how quickly Biocon and Viatris can convert market share in a ustekinumab biosimilar segment that now includes multiple approved competitors.

Source: Biocon via biocon.com, 18 August 2026.